Intravitreal Bevacizumab Injection for Choroidal Neovascularization Associated with Multifocal Choroiditis
Abstract
Purpose: To evaluate the long-term efficacy and safety of intravitreal bevacizumab injections for choroidal neovascularization (CNV) associated with multifocal choroiditis (MFC). Methods: This is a retrospective case series study. Patients who were treated with intravitreal bevacizumab injections for CNV associated with MFC from January 2004 to August 2016 were included. The characteristics of patients, change in best corrected visual acuity, and central subfield thickness (CST) were reviewed. Results: Among 34 MFC eyes (22 patients), 6 eyes (6 patients, 17.6%) had CNV associated with MFC. The mean age of patients was 41 (26-64) years and four of six patients (66%) were female. The mean duration of follow-up was 101.5 (36-178) months and the mean number (range) of intravitreal bevacizumab injections was 2.3 (1-6). Three of six (50%) eyes showed evident inflammation and were treated with immunosuppression agents. Visual acuity improved in five of six (83%) eyes and CST decreased in all eyes at final visit. One eye with initial poor visual acuity (2/100) continued to have poor final visual acuity (2/100) with scar changes. No adverse events were reported. Conclusions: Intravitreal bevacizumab injections were safe and effective at improving visual acuity and decreasing CST over long-term follow-up in a small series of patients with CNV secondary to MFC.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.